Streetbeat News

NAMS

NewAmsterdam Pharma Company N.V.

https://www.newamsterdampharma.com

Industry

Biotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Open

24.99

Mkt cap

2.3B

Volume

1.4M

High

25.17

P/E Ratio

-11.17

52-wk high

27.29

Low

24.38

Div yield

N/A

52-wk low

10.12

NewAmsterdam Pharma has successfully closed an upsized $479 million public offering of ordinary shares and pre-funded warrants, including the full exercise of the underwriters' option to purchase additional shares. This move is aimed at supporting the company's development of non-statin medicines for cardiovascular disease.

Portfolio Pulse from

December 13, 2024 | 10:30 pm

NewAmsterdam Pharma's drug obicetrapib showed positive results in a phase 3 study, reducing LDL-C in patients with ASCVD and HeFH. This success paves the way for a potential FDA application in 2025, with further data releases and publications as future catalysts.

Portfolio Pulse from

December 11, 2024 | 6:45 pm

NewAmsterdam Pharma has announced a $300 million public offering of ordinary shares and pre-funded warrants. The offering is aimed at raising funds for the company's development of non-statin medicines for cardiovascular disease. The offering's completion is subject to market conditions.

Portfolio Pulse from

December 10, 2024 | 9:45 pm

NewAmsterdam Pharma announced positive results from its Phase 3 BROADWAY trial for Obicetrapib, showing significant LDL-C reduction in patients with cardiovascular disease or familial hypercholesterolemia.

Portfolio Pulse from

December 10, 2024 | 12:15 pm

NewAmsterdam Pharma's stock plummeted despite positive results from a cholesterol study showing a 50% reduction in LDL. The market reaction suggests other factors may be influencing investor sentiment.

Portfolio Pulse from

November 20, 2024 | 3:30 pm

NewAmsterdam Pharma (NASDAQ:NAMS) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month price target range of $31.00 to $37.00, with an average of $33.75, slightly up from the previous $33.00. The company shows strong revenue growth but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 1:00 pm

Piper Sandler has reiterated its Overweight rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:30 pm

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:00 pm

Needham has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS), highlighting its cholesterol drug obicetrapib as a potential blockbuster. The drug showed significant LDL-C reduction in trials, and Needham has set a Buy rating with a $36 price target. Obicetrapib could generate over $2 billion in sales, targeting 30 million patients.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 5:33 pm

Needham analyst Serge Belanger has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and set a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:46 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.